CStone’s Sugemalimab Wins Top ESMO Backing for Stage III Lung Cancer

CStone Pharmaceuticals ( (HK:2616) ) has provided an announcement.

CStone Pharmaceuticals’ anti-PD-L1 antibody sugemalimab has received a [I, A] recommendation in the European Society for Medical Oncology guideline for consolidation therapy in patients with unresectable Stage III non-small cell lung cancer who have not progressed after chemoradiotherapy. This follows an earlier [I, A] ESMO recommendation for first-line treatment of metastatic Stage IV NSCLC, meaning both approved NSCLC indications for sugemalimab in the EU and UK are now embedded in ESMO guidance, highlighting its clinical value.

The latest guideline endorsement, based on Phase III GEMSTONE-301 trial data showing significant progression-free and meaningful overall survival benefits, is expected to accelerate market access for sugemalimab in the European Union and other regions. Together with existing approvals from the European Commission and UK regulators, and commercialization deals across more than 60 countries, the ESMO backing strengthens CStone’s global lung cancer franchise and may enhance its competitive positioning in the immuno-oncology market.

The most recent analyst rating on (HK:2616) stock is a Sell with a HK$5.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.

More about CStone Pharmaceuticals

CStone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative oncology therapies, with a particular emphasis on immuno-oncology drugs such as its core product sugemalimab. The company targets global markets including Europe, the Middle East, Africa and Latin America through multiple commercialization partnerships covering over 60 countries and regions.

Average Trading Volume: 10,499,399

Technical Sentiment Signal: Buy

Current Market Cap: HK$9.59B

See more insights into 2616 stock on TipRanks’ Stock Analysis page.